Buzdar A U, Smith T L, Powell K C, Blumenschein G R, Gehan E A
Breast Cancer Res Treat. 1982;2(2):163-9. doi: 10.1007/BF01806452.
Four hundred and sixty patients with stage II or III breast cancer following regional therapy were treated with an adjuvant combination chemotherapy consisting of fluorouracil, doxorubicin, and cyclophosphamide (FAC). The relationship between the length of disease-free survival and length of delays in initiation of chemotherapy after surgery was evaluated. Patients were divided into four subgroups according to the length of delay in initiation of chemotherapy (less than 10 weeks, 10-13, 14-17, and greater than or equal to 18 weeks). Overall four year disease-free survival was 64%, 68%, 60%, and 63% for patient groups with delays of less than 10 weeks, 10-13, 14-17, or greater than or equal to 18 weeks respectively (p = 0.39). There was no trend for longer delay in treatment to be associated with shorter disease-free survival, except in poor prognosis patients.
460例接受区域治疗后的II期或III期乳腺癌患者接受了由氟尿嘧啶、多柔比星和环磷酰胺（FAC）组成的辅助联合化疗。评估了无病生存期的长短与术后开始化疗的延迟时间之间的关系。根据开始化疗的延迟时间长短（少于10周、10 - 13周、14 - 17周以及大于或等于18周）将患者分为四个亚组。化疗延迟少于10周、10 - 13周、14 - 17周或大于或等于18周的患者组，其四年无病生存率分别为64%、68%、60%和63%（p = 0.39）。除了预后较差的患者外，治疗延迟时间较长与无病生存期较短之间没有相关性趋势。
